BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $178
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.
BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $151 to $178.